retatrutide type 2 diabetes phase 2 trial Reta clinical data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in 3 trials for metabolic health — targeting GLP-1, GIP 💉 A triple-action once-weekly injection

Easy application eliminates the fear of incorrect administration, improving accessibility and self-administration confidence

The so-called GLP-1 patches available in the market contain only natural ingredients

Food and Drug Administration approved the first GLP-1 medications in 2005

The pivotal STEP trials for semaglutide and SURMOUNT trials for tirzepatide included thousands of participants with monitoring for suicidal ideation using standardized tools such as the Columbia-Suicide Severity Rating Scale (C-SSRS), and did not demonstrate elevated rates compared to placebo groups

For individuals who cannot tolerate or afford GLP-1 RAs, options, including dietary food choices and probiotic nutritional supplements, are available

Rotating sites : Regularly switching injection sites helps prevent irritation, scarring, and fat tissue changes (lipodystrophy)